Trial · NCT07483801
Registered outcomes21
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 20 of 21
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Sub-study 1A:Change in forearm blood flow parameters after infusion of semaglutide (Ratio) | 2-2.5 months from screening to follow-up | Ratio, expressed as a number (no units as this is a ratio) |
| Primary | Sub-study 1A:Change in forearm blood flow parameters after infusion of semaglutide (Absolute flow) | 2-2.5 months from screening to follow-up | Absolute flow in the infused arm, in mL/min/100 mL |
| Primary | Sub-study 1A: Change in forearm blood flow parameters after infusion of semaglutide (Percentage Change) | 2-2.5 months from screening to follow-up | Percentage change in the infused arm, in % |
| Primary | Sub-study 1B: Change in forearm blood flow parameters after infusion of tirzepatide (Absolute flow) | 2-2.5 months from screening to follow-up | Absolute flow in the infused arm, in mL/min/100 mL |
| Primary | Sub-study 1B: Change in forearm blood flow parameters after infusion of tirzepatide (Ratio) | 2-2.5 months from screening to follow-up | Ratio, expressed as a number (no units as this is a ratio) |
| Primary | Sub-study 1B: Change in forearm blood flow parameters after infusion of tirzepatide (Percent Change) | 2-2.5 months from screening to follow-up | Percentage change in the infused arm, in % |
| Primary | Sub-study 1C: Change in forearm blood flow parameters after infusion of semaglutide or tirzepatide or saline (Absolute flow) | 2-2.5 months from screening to follow-up | Absolute flow in the infused arm, in mL/min/100 mL |
| Primary | Sub-study 1C: Change in forearm blood flow parameters after infusion of semaglutide or tirzepatide or saline (Ratio) | 2-2.5 months from screening to follow-up | Ratio, expressed as a number (no units as this is a ratio) |
| Primary | Sub-study 1C: Change in forearm blood flow parameters after infusion of semaglutide or tirzepatide or saline (Percentage change) | 2-2.5 months from screening to follow-up | Percentage change in the infused arm, in % |
| Primary | Sub-study 2A: Changes in cardiovascular haemodynamic variables after administration of semaglutide (Blood pressure) | 2-2.5 months from screening to follow-up | Blood pressure measured in mmHg |
| Primary | Sub-study 2A: Changes in cardiovascular haemodynamic variables after administration of semaglutide (Heart rate) | 2-2.5 months from screening to follow-up | Heart rate measured in beats per minute (bpm) |
| Primary | Sub-study 2A: Changes in cardiovascular haemodynamic variables after administration of semaglutide (Cardiac output) | 2-2.5 months from screening to follow-up | Cardiac output measured in L/min |
| Primary | Sub-study 2A: Changes in cardiovascular haemodynamic variables after administration of semaglutide (Vascular resistance) | 2-2.5 months from screening to follow-up | Vascular resistance measured in dynes⋅sec⋅cm5 |
| Primary | Sub-study 2B: Changes in cardiovascular haemodynamic variables after administration of tirzepatide (Blood pressure) | 2-2.5 months from screening to follow-up | Blood pressure measured in mmHg |
| Primary | Sub-study 2B: Changes in cardiovascular haemodynamic variables ) after administration of tirzepatide (Heart rate) | 2-2.5 months from screening to follow-up | Heart rate measured in beats per minute (bpm) |
| Primary | Sub-study 2B: Changes in cardiovascular haemodynamic variables after administration of tirzepatide (Cardiac output) | 2-2.5 months from screening to follow-up | Cardiac output measured in L/min |
| Primary | Sub-study 2B: Changes in cardiovascular haemodynamic variables after administration of tirzepatide (Vascular resistance) | 2-2.5 months from screening to follow-up | Vascular resistance measured in dynes⋅sec⋅cm5 |
| Primary | Sub-study 2C: Changes in cardiovascular haemodynamic variables after administration of semaglutide or tirzepatide or saline (Blood pressure) | 2-2.5 months from screening to follow-up | Blood pressure measured in mmHg |
| Primary | Sub-study 2C: Changes in cardiovascular haemodynamic variables after administration of semaglutide or tirzepatide or saline (Heart rate) | 2-2.5 months from screening to follow-up | Heart rate measured in beats per minute (bpm) |
| Primary | Sub-study 2C: Changes in cardiovascular haemodynamic variables after administration of semaglutide or tirzepatide or saline (Cardiac output) | 2-2.5 months from screening to follow-up | Cardiac output measured in L/min |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT07483801/registered